Souhaitez-vous accéder aux communiqués récents ?

Regeneron shares corporate progress and highlights from the Company’s broad and diverse investigational pipeline.

Primary endpoint of DFS met at first prespecified interim analysis, showing a 68% reduction in the risk of disease recurrence or death in patients with high-risk CSCC after surgery compared to placebo...

Researchers have developed a highly efficient gene editing therapy that could potentially treat Stargardt disease, the most common form of inherited macular degeneration. This groundbreaking study,...

Vabysmo PFS is the first and only prefilled syringe containing a bispecific antibody, offering a convenient alternative to currently available Vabysmo vialsVabysmo has demonstrated rapid and robust...

Dublin, Dec. 04, 2024 (GLOBE NEWSWIRE) -- The "United States Retinal Surgery Devices Market Report Forecast by Product, Application, End-user, Countries and Company Analysis 2024-2032" report has...

·More than 530 million people worldwide living with diabetes are at risk for developing diabetic retinal disease (DRD), the leading cause of blindness in working-age adults. 1·DRD is a growing...

Dublin, Nov. 05, 2024 (GLOBE NEWSWIRE) -- The "Ophthalmoscopes Market - Focused Insights 2024-2029" report has been added to ResearchAndMarkets.com's offering.The Ophthalmoscopes Market was valued...

Arizona Family’s Journey: A Race Against Blindness grants $1M to Bardet-Biedl Syndrome research, fueling hope and potential cures for childhood blindness.

Initiative will test Grifols ocular surface immunoglobulin (OSIG) eye drops to evaluate their nonclinical efficacy in neutralizing symptoms from exposure to sulfur mustard, a chemical warfare agent ...

The ELEVATUM study showed clinically meaningful improvement in vision and reduction in retinal fluid in people with diabetic macular edema (DME) treated with Vabysmo who identify as African American,...